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Introduction: Mesenchymal stem cells (MSCs) have potential for re-epithelization and recovery in acute respiratory
distress syndrome (ARDS). In a previous in vitro study, the results showed that the canonical Wnt/β-catenin pathway
promoted the differentiation of MSCs into type II alveolar epithelial cells, conferred resistance to oxidative stress,
and promoted their migration, suggesting that the Wnt/β-catenin pathway might be one of the key mechanisms
underling the therapeutic effect of mouse MSCs in ARDS.
Methods: Mouse MSCs stable transfected with β-catenin or green fluorescent protein control were transplanted
intratracheally into the ARDS mice induced by lipopolysaccharide. Lung tissue injury and repair assessment were
examined using haematoxylin and eosin staining, lung injury scoring, Masson’s trichrome staining and fibrosis
scoring. Homing and differentiation of mouse MSCs were assayed by labelling and tracing MSCs using NIR815
dye, immunofluorescent staining, and Western immunoblot analysis. The inflammation and permeability were
evaluated by detecting the cytokine and protein measurements in bronchoalveolar lavage fluid using enzyme-linked
immunosorbent assay.
Results: In this study, β-catenin-overexpressing MSC engraftment led to more significant effects than the GFP controls,
including the retention of the MSCs in the lung, differentiation into type II alveolar epithelial cells, improvement in
alveolar epithelial permeability, and the pathologic impairment of the lung tissue.
Conclusion: These results suggest that the activation of canonical Wnt/β-catenin pathway by mouse MSCs by
overexpressing β-catenin could further improve the protection of mouse MSCs against epithelial impair and the
therapeutic effects of mouse MSCs in ARDS mice.Introduction
Acute respiratory distress syndrome (ARDS) is the major
cause of acute respiratory failure in critically ill patients,
with a mortality as high as 40% despite improvements in
supportive care [1,2]. The physiological hallmark of
ARDS is the disruption of the alveolar-capillary mem-
brane barrier, leading to development of noncardiogenic
pulmonary oedema, in which a proteinaceous exudate
floods the alveolar spaces, impairs gas exchange, and* Correspondence: haiboq2000@gmail.com
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unless otherwise stated.precipitates respiratory failure. Therefore, the repair and
regeneration of the alveolar epithelium is associated with
the treatment of ARDS [3].
Mesenchymal stem cells (MSCs), with their properties
of multipotency and immunoregulation, are able to
differentiate into alveolar epithelial cells, promote re-
epithelialisation, alleviate inflammation, improve patho-
logical impairment, and even reduce mortality in ARDS
models [4-6]. However, the therapeutic effects remain
limited because of the low engraftment and differenti-
ation rates of MSCs in the lung tissue of ARDS models
[7,8]. Therefore, clarifying the mechanisms underlyings is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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the improvement of cellular retention in injured lung tis-
sue, differentiation of MSCs into alveolar epithelial cells
and the MSC-mediated therapeutic effects in ARDS.
The canonical Wnt signalling pathway, which de-
pends on the accumulation of β-catenin, is one of the
fundamental pathways in cell proliferation and motility,
cell fate decisions, cell polarity during embryonic devel-
opment and adult tissue homeostasis [9]. Several recent
studies have shown that Wnts and their downstream
canonical signalling have critical effects on the self-
renewal and differentiation of MSCs, which express a
number of ligands, receptors, and inhibitors of the Wnt
pathway [10].
In our previous study, we found that activation of the
canonical Wnt/β-catenin pathway promotes the differen-
tiation of mouse bone marrow-derived MSCs (mMSCs)
into type II alveolar epithelial (AT II), confers resistance
to oxidative stress, and promotes their migration to in-
jured lung tissue in vitro [11]. However, the role of the
Wnt/β-catenin pathway in the fate and therapeutic effect
of MSCs in ARDS remains unexplored in vivo, where a
more complicated environment and regulatory mecha-
nisms different from the specific and limited cultural
conditions of in vitro differentiation may affect the
MSCs. In our previous study, a long-term, stable mMSC
line modified with activated β-catenin was constructed
using lentiviral vectors and confirmed to be able to acti-
vate the Wnt/β-catenin pathway, which could regulate
the proliferation, migration and differentiation of the
MSCs; this cell line is suitable for in vivo investigations
[12]. The aim of our current study was to identify the ef-
fect of β-catenin overexpression on the repair of injured
alveolar epithelium and its overall therapeutic effect in
lipopolysaccharide (LPS)-induced ARDS mice.Materials and methods
Mesenchymal stem cell transfection and culture
mMSCs derived from the bone marrow of C57BL/6
mice was obtained from Cyagen Biosciences, Inc.
(Guangzhou, China). The details of the transfection of
MSCs by lentivirus vectors were described in our previ-
ous work [12]. After transfection, mMSCs carrying an
empty vector and enhanced green fluorescence protein
(eGFP) (control mMSCs) or mMSCs carrying both the
β-catenin gene and eGFP (mMSC-Ctnnb1) were cul-
tured in a 1:1 mix of Dulbecco’s modified Eagle
medium/nutrient mixture F-12 (Wisent, Inc., St-Bruno,
Quebec, Canada) containing 10% foetal bovine serum
(Wisent, Inc.) and 1% antibiotics (streptomycin and
penicillin) and were incubated at 37°C in a humidified
atmosphere of 5% CO2. The cells were used at passages
6 to 10 for the experiments.Preparation of experimental animals
Male C57BL/6 mice, aged 8 to 12 weeks and weighing
20 to 25 g, were obtained from the Laboratory Animal
Center at the Academy of Military Medical Sciences
(Beijing, China). All animal experiments performed in
this study conformed to the Guide for the Care and
Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee.
Murine model of lipopolysaccharide-induced acute re-
spiratory distress syndrome
The mice were first anaesthetised with pentobarbital
(50 mg/kg) by intra-peritoneal injection and received a
single dose of LPS (100 μg intratracheally (i.t.)) from
Escherichia coli serotype 0111:B4 (Sigma-Aldrich, St
Louis, MO, USA) in 50 μl sterile normal saline (NS)
[13]. The mice were then allowed to recover in a 100%
oxygen chamber until fully awake. The control mice re-
ceived 0.9% NS instead of LPS.
Experimental protocol
The mice were randomly divided into four groups (n =
36 for each group): the NS + PBS group, in which mice
received 30 μl phosphate-buffered saline (PBS) i.t.
4 hours after instillation of 0.9% NS i.t.; the LPS + PBS
group, in which mice received 30 μl PBS i.t. 4 hours after
the induction of ARDS; the LPS +mMSC control group,
in which mice received control mMSCs (500,000 cells in
30 μl PBS) i.t. 4 hours after the induction of ARDS; and
the LPS +mMSC-Ctnnb1 group, in which mice received
mMSC-Ctnnb1 (500,000 cells in 30 μl PBS) i.t. 4 hours
after the induction of ARDS. The mice were sacrificed
after 3, 7 or 14 days, and samples were collected from
each mouse for lung injury assessment, biochemical ana-
lysis, and histology. A diagram of the experimental
protocol is shown in Figure 1.
Haematoxylin and eosin staining and lung injury scoring
The right upper lobe was embedded in paraffin and sa-
gittally sliced at 5 μm. The sections were stained with
haematoxylin and eosin. Oedema, alveolar and intersti-
tial inflammation and haemorrhage, atelectasis, necrosis,
and hyaline membrane formation were each scored
using a 0 to 4 point scale (0, no injury; 1, injury in 25%
of the field; 2, injury in 50%; 3, injury in 75%; and 4, in-
jury throughout the field). The total lung injury score
was calculated as the sum of these scores [14]. Ten ran-
domly selected high-power fields (400×) in each slide
were analysed by two investigators who were blinded to
the mouse groups.
Labelling and tracing of mesenchymal stem cells
The cultured control mMSCs and mMSC-Ctnnb1 were
labelled with CellVue NIR815 dye (eBioscience Inc., San
Figure 1 Diagram of the experimental protocol. BALF, bronchoalveolar lavage fluid; i.t., intratracheally; LPS, lipopolysaccharide; mMSC, mouse
mesenchymal stem cell; NS, normal saline; PBS, phosphate-buffered saline.
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tions. NIR815-labelled cells (5 × 105) were directly in-
stilled into the trachea of the LPS +mMSC control and
LPS +mMSC-Ctnnb1 mice. Ex vivo lungs from three
subjects per group were imaged at three time points
(3, 7 and 14 days post-instillation) using a Maestro In-Vivo
Optical Imaging system (excitation = 786 nm, emission =
814 nm, exposition time 4,000 ms; Caliper Life Sciences,
MA, Boston, USA) [15]. The autofluorescence spectra were
then unmixed based on their spectral patterns using the
Maestro 2.4 software (Caliper Life Sciences). The fluores-
cence intensity of the lungs was measured by placing the
regions of interest on the organ, and the average signals
were normalised based on the exposure time and the area
of the region of interest (scaled counts/second).
Immunofluorescent staining
Immunofluorescent staining for the detection of MSC
engraftment homing and differentiation in vivo were
performed as previously described [16]. Briefly, the left
lung tissue samples from the LPS +mMSC control
group and the LPS +mMSC-Ctnnb1 group were snap-
frozen in liquid nitrogen then stored at −80°C until use.
The tissue was embedded in optimal cutting temperature
(Thermo Fisher Scientific, Bremen, Germany), and cut at
a thickness of 10 μm. The slides were fixed in acetone at
4°C for 15 minutes and then blocked with 3% bovine
serum albumin in PBS/0.3% Triton X-100 for 30 minutes
at room temperature. After washing and draining, the
slides were incubated overnight at 4°C with a green fluor-
escent protein (GFP) primary antibody (1:100, Abcam
Incorporated, Cambridge, MA, USA) alone or with the
same volume of GFP and pro-surfactant protein C (SP-C)
primary antibodies (1:100, Santa Cruz Biotechnology, Paso
Robles, CA, USA). After three washes with PBS, these
slides were incubated with secondary Goat Anti-Mouse
Alexa Fluor® 488 and Goat Anti-Rabbit Alexa Fluor® 647
antibodies (Abcam Incorporated) at a 1:200 dilution in 2%
bovine serum albumin for 1 hour at 37°C in the dark. The
nuclei were stained with DAPI for 5 minutes. The imageswere captured using a fluorescence microscope (Olympus,
Tokyo, Japan). The retention or differentiation of trans-
planted MSCs was quantified based on the count of GFP-
positive MSCs or the ratio of the count of GFP-positive to
the count of SP-C-positive MSCs in randomly selected
high-power fields (400×) for each slide by histopathologists
blinded to the protocol design.
Western immunoblot analysis
Total protein lysates were extracted using RIPA lysis buffer.
The protein was separated by SDS-PAGE and electro-
transferred to PVDF membranes (Millipore, Bedford, MA,
USA). The membranes were blocked in Tris-buffered saline
containing 0.1% Tween-20 and 5% bovine serum albumin
for 1 hour at room temperature and then incubated at
4°C overnight with primary antibodies recognising SP-C,
β-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), or occludin (Abcam Incorporated). Immunoreactive
bands were detected with chemiluminescence reagents
(Thermo Fisher Scientific, Bremen, Germany).
Cytokine and protein measurements in bronchoalveolar
lavage fluid
Bronchoalveolar lavage fluid (BALF) was collected by
flushing 1 ml ice-cold PBS back and forth three times
through a tracheal cannula and then centrifuged at 800 g
for 10 minutes. The concentrations of the interleukin (IL)-
1β, IL-6 and IL-10 proteins in the supernatant were mea-
sured using murine cytokine-specific enzyme-linked im-
munosorbent assay (ELISA) kits (ExcellBio, Shanghai,
China) strictly according to the manufacturer’s instructions.
The amounts of total protein and albumin in the BALF
were measured as a marker of epithelial permeability using
ELISA kits (Cusabio Biotech, Wuhan, China). In addition,
the levels of keratinocyte growth factor (KGF) in the BALF
were measured using ELISA kits (Cusabio Biotech).
Evaluation of the lung oedema
Lung oedema was evaluated using the ratio of lung wet
weight to body weight (LWW/BW) measured as
Cai et al. Stem Cell Research & Therapy  (2015) 6:65 Page 4 of 11previously described [17]. Briefly, the whole lung was re-
moved and cleared of all extrapulmonary tissues and the
LWW/BW was calculated based on the values of lung
wet weight and body weight (mg/g).
Masson’s trichrome staining and fibrosis scoring
The lung sections were stained sequentially with
Weigert’s iron haematoxylin solution, Biebrish scarlet-
acid fuchsin solution, and aniline blue solution; a blue
signal indicated positive staining for collagen. The cri-
teria of Ashcroft were used [18], and lung fibrosis was
quantified based on the findings in ten randomly se-
lected high-power fields (400×) for each slide by histopa-
thologists blinded to the protocol design.
Statistical analysis
The data are presented as the means ± standard deviation.
Statistical analyses were performed using SPSS 16.0 soft-
ware package (SPSS Inc., Chicago, IL, USA). Comparisons
among multiple groups were performed using one-way
analysis of variance followed by Bonferroni’s post-hoc test
if the data were normally distributed. A P value less than
0.05 was considered to be statistically significant.
Results
Effect of β-catenin-overexpressing mesenchymal stem cells
on the pulmonary histopathology of lipopolysaccharide-
induced acute respiratory distress syndrome mice
An increased thickening of the alveolar wall, alveolar and
interstitial inflammatory cell infiltration, haemorrhaging, al-
veolar exudates, and oedema were found in the lung tissue
of mice after LPS-induced lung injury, and the Smith score
for quantification of the lung injury was also increased.
However, these histopathologic characteristics and the
Smith score were alleviated at 3, 7, and 14 days in the
LPS +mMSC control and LPS +mMSC-Ctnnb1 groups
compared with the LPS + PBS group (P < 0.05). The effect
was greater in the LPS +mMSC-Ctnnb1 group than in the
LPS +mMSC control group (P < 0.05) (Figure 2A,B).
Overexpression of β-catenin increases the retention of
mesenchymal stem cells in the lung after lipopolysaccharide
challenge
Ex vivo NIR imaging was performed on the lungs from
LPS +mMSC control and LPS +mMSC-Ctnnb1 mice 3,
7 and 14 days after MSC administration to trace the
intrapulmonary mMSCs. Colour-coded fluorescence im-
ages indicated that the signals in the LPS +mMSC-
Ctnnb1 group were stronger than those in the LPS +
mMSC control group at the end of days 3, 7 and 14 after
the LPS challenge. For each group, the signal gradually
reduced after day 3. Though the signal decreased signifi-
cantly on day 14 after the LPS challenge, it could still be
detected (Figure 3A). Similar results were also observedusing an immunofluorescent staining assay to detect the
MSCs in lung tissue (Figure 3B).
Overexpression of β-catenin promotes the differentiation
of mesenchymal stem cells into type II alveolar epithelial
cells in vivo
Differentiation of the MSCs into AT II cells was evalu-
ated 14 days after the MSC administration by analysing
the expression of SP-C, a specific AT II cell marker, in
the engrafted MSCs by immunofluorescence staining.
Co-localisation of SP-C (red) and MSCs (green) in the
lung tissue, which appeared yellow, could be seen in
both the LPS +mMSC-Ctnnb1 and LPS +mMSC control
groups; however, mMSC-Ctnnb1 treatment led to a
higher differentiation efficiency of the MSCs into AT II
cells than the control treatment (Figure 4A). The total
expression of SP-C protein in the lung tissue 14 days
after MSC administration was evaluated using Western
blotting analysis. The results showed that SP-C protein
was upregulated in the LPS + mMSC control group and
the LPS + mMSC-Ctnnb1 group compared with the
LPS + PBS group (P < 0.05), and the increase in the LPS +
mMSC-Ctnnb1 group was more significant than the increase
in the LPS +mMSC control group (P < 0.05) (Figure 4B).
β-Catenin-overexpressing mesenchymal stem cells
improved lipopolysaccharide-induced lung permeability
LWW/BW was calculated to evaluate lung oedema.
LWW/BW was significantly reduced in the LPS +
mMSC-Ctnnb1 group compared with the LPS + PBS
group at days 3, 7 and 14 (P < 0.05) and in the LPS +
mMSC control group at days 3 and 14 (P < 0.05). At day
14, LWW/BW was almost restored to normal levels in
the LPS +mMSC-Ctnnb1 group (Figure 5A).
To evaluate the effect of β-catenin-overexpressing
MSCs on epithelial permeability of the lung, the total
protein and albumin concentrations in the BALF were
measured using mouse-specific ELISAs. Total protein
and albumin were significantly reduced in the LPS +
mMSC-Ctnnb1 group compared with the LPS + PBS
group (P < 0.05) and the LPS +mMSC control group on
days 3, 7 and 14 (P < 0.05). Significant decreases in total
protein and albumin were also observed in the LPS +
mMSC control group compared with the LPS + PBS
group on days 3 and 7 (P < 0.05), while no difference
was observed on day 14 (Figure 5B,C).
Additionally, to analyse the tight junctions of the pul-
monary epithelial cells after MSC administration, occlu-
din protein expression was evaluated in the lung tissue
14 days after MSC administration using Western blot-
ting analysis. The results showed that occludin protein
was upregulated in the LPS +mMSC control and LPS +
mMSC-Ctnnb1 groups compared with the LPS + PBS
group (P < 0.05), and the increase observed in the LPS +
Figure 2 Effect of control mouse mesenchymal stem cells (mMSCs) or β-catenin-overexpressing mMSCs on the histopathology of lipopolysaccharide
(LPS)-induced lung injury and survival over 14 days. (A) Histopathological analysis of lung tissues from mice of all the experimental groups
were performed at days 3, 7 and 14 after the LPS challenge (haematoxylin and eosin staining, magnification 200×). (B) Quantification of lung
injury showed a significant reduction in the severity of lung injury in the LPS + mMSC control and LPS + mMSC-Ctnnb1 mice. The change was
more significant in the LPS + mMSC-Ctnnb1 group than in the LPS + mMSC control group; n = 6 at each time point for each group. The results
are expressed as the mean ± standard deviation. *P < 0.05, versus normal saline (NS) + phosphate-buffered saline (PBS) group; #P < 0.05, versus
LPS + PBS group; &P < 0.05, versus LPS + mMSC control group.
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the LPS +mMSC control group (P < 0.05) (Figure 5D).
The concentration of KGF, an important cytokine for the
improvement of lung permeability, was measured in BALF
using a mouse-specific ELISA. KGF was significantly in-
creased in the LPS + PBS, LPS +mMSC control and LPS +
mMSC-Ctnnb1 groups compared with the NS + PBS group
on days 3, 7 and 14 (P < 0.05). Both control mMSC and
mMSC-Ctnnb1 administration decreased the expression of
KGF on day 3 compared with LPS + PBS treatment (P <
0.05). On day 14, KGF was higher in the LPS +mMSC-
Ctnnb1 group than in the LPS + PBS (P < 0.05) and LPS +
mMSC control groups (P < 0.05) (Figure 5E).
β-Catenin-overexpressing mesenchymal stem cells
attenuated acute lipopolysaccharide-induced pulmonary
inflammation
The levels of the pro-inflammatory cytokines IL-1β and
IL-6 and the anti-inflammatory cytokine IL-10 weremeasured in the BALF of mice 3 days after LPS treat-
ment using ELISA. All three cytokines were significantly
higher in the LPS + PBS group than in the NS + PBS
group (P < 0.05). IL-1β and IL-6 were reduced in the
LPS +mMSC control and LPS +mMSC-Ctnnb1 groups
compared with the LPS + PBS group (Figure 6A,B), while
IL-10 was increased (Figure 6C) (P < 0.05). Compara-
tively, the decrease in IL-1β and increase in IL-10 ob-
served in the LPS +mMSC-Ctnnb1 group were more
significant than the changes observed in the LPS +
mMSC control group (P < 0.05).
β-Catenin-overexpressing mesenchymal stem cells
inhibited lung fibrosis
The deposition of collagen in lung tissue after 14 days of
LPS exposure was evaluated by Masson’s trichrome
staining and was markedly increased in the LPS + PBS,
LPS +mMSC control and LPS +mMSC-Ctnnb1 groups
compared with the NS + PBS group (P < 0.05). Reduced
Figure 3 Effect of β-catenin overexpression on the retention of mouse mesenchymal stem cells (mMSCs) in the lung after lipopolysaccharide
(LPS) challenge. (A) Ex vivo NIR imaging of the lungs. Representative photographs of colour-coded fluorescence images are shown from
three mouse lungs obtained 3, 7 and 14 days after mMSC administration from the LPS + mMSC control and LPS + mMSC-Ctnnb1 groups.
(B) Immunofluorescent staining to detect mMSC engraftment in lung tissue is shown as green fluorescent protein (GFP)-positive (green;
white arrows point to the GFP-positive cells). The nuclei were stained with DAPI (blue). Representative photographs are shown from six
mouse lungs 3, 7 and 14 days after mMSC administration from the LPS+ mMSC control and LPS +mMSC-Ctnnb1 groups. All microphotographs were
taken at 400× magnification (scale bar = 20 μm). The count of GFP-positive MSCs in randomly selected high-power fields (count/field) represent the
mean ± standard deviation (n = 6). &P < 0.05, versus LPS +mMSC control group.
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with either GFP-transfected MSCs or Ctnnb1-transfected
MSCs when compared with LPS + PBS (P < 0.05), but the
decrease observed in the LPS +mMSC-Ctnnb1 group was
more significant than that observed in the LPS +mMSC
control group (P < 0.05) (Figure 7).
Discussion
MSCs have been shown to migrate to and engraft in in-
jured lungs and differentiate into lung epithelial cells
in vivo and have been considered to be a potential treat-
ment for ARDS [4-6,19]. However, the relatively low en-
graftment and differentiation rate of MSCs in the
injured lungs [4,7,8] limit their beneficial effects for
ARDS therapy. In our previous in vitro study, we found
that activation of the canonical Wnt/β-catenin pathway
promoted the differentiation of mMSCs into AT II cells,
migration to injured lung tissue, and resistance to oxida-
tive stress [11]. This suggested that the canonical Wnt
pathway may contribute to the improved therapeutic
value of MSCs in ARDS. In the present study, we con-
firmed this positive effect of the Wnt/β-catenin pathway
on LPS-induced ARDS mice using MSCs stably trans-
fected with the β-catenin gene.
The canonical Wnt pathway is a fundamental regula-
tory pathway in development, differentiation, and other
physiological functions of cells and organisms [9].
Canonical Wnt activation mainly depends on the accu-
mulation of β-catenin. The binding of canonical Wnt li-
gands to the Frizzled (Fz) co-receptors and low-density
lipoprotein receptor-related protein (LRP) 5 or 6 resultsin the inhibition of glycogen synthase kinase-3β (GSK-
3β) and the accumulation of β-catenin, which then
translocates into the nucleus to regulate target gene ex-
pression [20]. Therefore, β-catenin is considered to be
the key signalling regulator of the canonical Wnt path-
way. To obtain MSCs with stable, long-term transgene
expression of β-catenin, lentiviral vectors were used for
transfection in our study. According to our previous
study, the lentiviral vector transduction efficiencies were
as high as 95% even 20 passages after transduction, and
the overexpression of β-catenin in the mMSCs led to the
nuclear accumulation of β-catenin, suggesting increased
activation of the Wnt/β-catenin pathway [12].
This construction of stable, long-term mMSCs lines
with altered canonical Wnt signalling was also con-
firmed in our previous study by changes in cellular
phenotype as well as altered biological behaviours in-
cluding proliferation, differentiation, and migration of
the mMSCs [12]. These characteristics suggested that
the gene modification might facilitate ARDS therapy, and
the observation that the administration of β-catenin-
overexpressing mMSCs improved both the histopatho-
logical morphology and survival of ARDS mice more than
treatment with mMSCs alone confirmed the benefits of β-
catenin-overexpressing mMSCs for ARDS.
The biological functions of MSCs, including anti-
inflammatory properties and abilities to differentiate into
specialised cell types and mediate the repair of injured
tissue, are based on their concentration and localisation
in the injured or inflamed sites. Many studies have
highlighted the ability of systemically or locally
Figure 4 Effect of β-catenin overexpression on the differentiation of mouse mesenchymal stem cells (mMSCs) into type II alveolar epithelial (AT II)
cells in vivo. (A) The differentiation of mMSCs into AT II cells was detected by immunofluorescence staining 14 days after mMSC administration in mice
from the lipopolysaccharide (LPS) +mMSC control and LPS +mMSC-Ctnnb1 groups. mMSC engraftment in lung tissue appears green fluorescent
protein (GFP)-positive (green), a specific AT II cell marker pro-surfactant protein C (SP-C) appears red, and co-localisation in each case appears
yellow (the white arrows point to double-positive cells). The nuclei were stained with DAPI (blue). All microphotographs were taken at 400×
magnification (scale bar = 20 μm). The ratio of the count of GFP-positive to the count of SP-C-positive MSCs in randomly selected high-power
fields is presented as mean ± standard deviation (n = 6). &P < 0.05 versus LPS + mMSC control group. (B) The expression of the SP-C protein in
the lung tissue on day 14 after mMSC administration was evaluated using Western blotting analysis. β-actin was used as an internal control,
and the results represent the mean ± standard deviation (n = 6). *P < 0.05 versus normal saline (NS) + phosphate-buffered saline (PBS) group;
#P < 0.05, versus LPS + PBS group; &P < 0.05, versus LPS + mMSC control group.
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traumatised, ischaemic, and tumourous tissues [21-25]
and their ability to specifically colonise the injured site,
rather than intact loci [26]. Likewise, several studies have
observed the enhanced recruitment of transplanted
MSCs to the lung tissue in ARDS mice compared to
normal control mice [5,27]. The positive effect of canon-
ical Wnt/β-catenin signalling on the migration of MSCs
has been demonstrated recently in other studies [28,29].
Our previous study also found that the migration of
mMSCs to injured lung tissue through Transwell cham-
bers was significantly enhanced when canonical Wnt sig-
nalling was stimulated by Wnt3a or LiCl [11]. In
agreement with these studies, the results presented here
show that β-catenin-overexpressing mMSCs exhibited
increased retention in the lung of LPS-induced ARDS
mice compared with control mMSCs.In addition to the increased migration, the increased
retention of MSCs in the lung tissue of ARDS mice may
have a protective effect against adverse factors that de-
crease survival of the transplanted MSCs in complex
in vivo situations, such as the production of oxidants, in-
flammatory factors, hypoxia, ischaemia, and so forth. In
our previous study, we discovered that canonical Wnt
signalling protected mMSCs against oxidative stress
damage, which was evident by increased survival and in-
hibition of apoptosis [11], and that the β-catenin-
overexpressing mMSCs exhibited increased proliferation
compared with control MSCs in vitro. All of these
mechanisms may contribute to the increased retention
of mMSCs in the lung after LPS challenge.
AT II cells are characterised by their ability to synthe-
sise and secrete alveolar surfactant that reduces surface
tension and prevents collapse of the alveoli and by their
Figure 5 Effect of control mouse mesenchymal stem cells (mMSCs) or β-catenin-overexpressing mMSCs on lipopolysaccharide (LPS)-induced lung
permeability. (A) Lung oedema was measured using the ratio of lung wet weight to body weight (LWW/BW). The results are shown for samples
taken 3, 7 and 14 days after LPS exposure. (B) Total protein (TP) and (C) albumin (ALB) concentration in bronchoalveolar lavage fluid (BALF) were
measured using mouse-specific enzyme-linked immunosorbent assays to evaluate the epithelial permeability of the lung. (D) Expression of the
occludin protein in the lung tissue on day 14 after mMSC administration was evaluated using Western blotting analysis. β-actin was used as an
internal control. (E) Keratinocyte growth factor (KGF) concentration in BALF was measured using a mouse-specific enzyme-linked immunosorbent
assay. The data represent the mean ± standard deviation of six animals at each time point per group. *P < 0.05, versus normal saline (NS) + phosphate-
buffered saline (PBS) group; #P < 0.05, versus LPS + PBS group; &P < 0.05, versus LPS+ mMSC control group).
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that serve as progenitor cells for re-epithelialisation of
impaired alveoli, significant in both physiological and
pathological conditions [30]. The repair and regener-
ation of injured AT II cells is therefore critical for theFigure 6 Effect of control mouse mesenchymal stem cells (mMSCs) or mM
pulmonary inflammation. Levels of the proinflammatory cytokines (A) int
bronchoalveolar lavage fluid (BALF) in mice receiving MSCs at 3 days afte
using enzyme-linked immunosorbent assay. Data are expressed as mean
phosphate-buffered saline (PBS) group; #P < 0.05, versus LPS + PBS group;recovery of patients with ARDS [31]. MSCs were proved
in several investigations to be able to differentiate into
AT II cells in vivo and in vitro [32,33]. Our previous
study also demonstrated that canonical Wnt signalling is
activated during the differentiation of mMSCs into AT IISCs overexpressing β-catenin on acute lipopolysaccharide (LPS)-induced
erleukin (IL)-1β, (B) IL-6 and anti-inflammatory cytokine (C) IL-10 in
r LPS-induced acute respiratory distress syndrome were measured
± standard deviation (n = 6). *P < 0.05, versus normal saline (NS) +
&P < 0.05, versus LPS+ mMSC control group.
Figure 7 Effect of control mouse mesenchymal stem cells (mMSCs) or mMSCs overexpressing β-catenin on lung fibrosis. (A) The lung fibrosis
was evaluated by Masson’s trichrome staining 14 days after lipopolysaccharide (LPS) exposure (200×). (B) The quantification of lung fibrosis is
shown as arbitrary units (n = 6). *P < 0.05, versus normal saline (NS) + phosphate-buffered saline (PBS) group; #P < 0.05, versus LPS + PBS group;
&P < 0.05, versus LPS +mMSC control group.
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pression of specific AT II cell markers [11]. Consistently,
our present study showed that the activation of the
canonical Wnt pathway through overexpression of β-
catenin in mMSCs significantly increased their differen-
tiation into AT II cells in the lung after LPS challenge.
Injury of the alveolar epithelium in ARDS is consid-
ered to be a key factor in the leakage of protein-rich
oedema fluid into the interstitium and alveolar space
[34]. Many studies have found that MSC treatment sig-
nificantly reduces the lung wet-to-dry ratio, the amount
of excess lung water, and the level of BALF protein, a
marker of endothelial and epithelial permeability, in ex-
perimental ARDS [7,35]. In our study, we demonstrated
that the β-catenin-overexpressing mMSCs also signifi-
cantly improved the epithelial permeability, as evident
from the LWW/BW, BALF albumin and total protein. It
should be noted that the reduced total protein and albu-
min concentrations in the BALF is also attributed to the
increased permeability of endothelium. As some studies
found MSCs could preserve vascular endothelial integ-
rity in the injured lungs after haemorrhagic shock [36],
and even might differentiate into endothelial cells fol-
lowing bleomycin-induced lung injury [32], the effects of
MSCs on the endothelial permeability in LPS-induced
ARDS mice and whether β-catenin is involved in these
effects is worth exploring in further studies.
The permeability barrier in the terminal airspace of
the lung is due in a large part to tight junctions between
alveolar epithelial cells [37]. Occludin is one of the well-
characterised tight junction proteins and provides most
of the barrier function of tight junctions [38]. Functionalopening of the tight junction barrier and downregulation
of occludin protein expression has been observed in
acute lung injury in adult animals [39]. Our results pre-
sented here showed that the expression of occludin pro-
tein in the lung tissue was downregulated after LPS
challenge and that mMSC treatment inhibited the repres-
sion of occludin protein. Moreover, the overexpression of
β-catenin in mMSCs may provide additional benefits.
KGF, which is capable of stimulating proliferation and
migration in AT II cells leading to the propagation of al-
veolar epithelial restitution [40] and reducing lung
oedema and inflammation, was mechanistically impli-
cated in the beneficial effect of MSCs on alveolar fluid
clearance in ARDS. In our study, the results showed that
treatment with β-catenin-overexpressing mMSCs mark-
edly increased BALF KGF compared with treatment with
mMSCs alone at day 14 after LPS instillation. These
results indicated that the further improvement in lung
permeability observed after treatment with β-catenin-
overexpressing mMSCs may contribute to the repair of
tight junctions and the increased paracrine signalling of
KGF from the mMSCs.
MSCs can regulate the activity of a broad range of im-
mune cells [41,42] and were found in several investiga-
tions, including the present study, to be able to inhibit
inflammation in ARDS in vivo. Several lines of evidence
supported this conclusion: pro-inflammatory cytokines
such as interferon-γ, IL-1β, IL-6 were reduced, while the
anti-inflammatory cytokine IL-10 was increased [7,27].
The overexpression of β-catenin in the mMSCs ampli-
fied this effect; however, the underlying mechanisms re-
main unclear and should be explored in the future.
Cai et al. Stem Cell Research & Therapy  (2015) 6:65 Page 10 of 11In addition to the alveolar epithelial cells, engrafted
MSCs in the lung could also differentiate into lung fibro-
blasts, myofibroblasts and interstitial monocytes, which
may participate in pulmonary fibrosis [32]. The activa-
tion of Wnt/β-catenin signalling may be involved in the
pulmonary fibrosis. Konigshoff and colleagues [43] dem-
onstrated that dysregulation of Wnt/β-catenin signalling
in AT II cells has been linked to the pathogenesis of pul-
monary fibrosis. Moreover, Chilosi and colleagues [44]
suggested that the aberrant nuclearisation of β-catenin in
bronchiolar lesions could promote epithelial-mesenchymal
transitions in the diseased lung. Another study found that
β-catenin in the alveolar epithelium protected from
lung fibrosis after intratracheal bleomycin [45]. Based
on these observations, we evaluated whether the β-
catenin-overexpressing mMSCs or control mMSCs
alone increased the risk of pulmonary fibrosis after
intratracheal LPS. The results of the present study
showed that lung fibrosis decreased after treatment
with control mMSCs alone and that this effect was
more significant after the engraftment of β-catenin-
overexpressing mMSCs.
Conclusion
Activation of the canonical Wnt/β-catenin pathway
through the overexpression of β-catenin increased the
retention of mMSCs in the lung, promoted the differen-
tiation of mMSCs into AT II cells, further improved the
lung epithelial permeability, further attenuated acute
pulmonary inflammation, and further inhibited lung fi-
brosis compared with control mMSCs, thus contributing
to an improved therapeutic effect of mMSCs in ARDS.
Abbreviations
ARDS: acute respiratory distress syndrome; AT II: type II alveolar epithelial;
BALF: bronchoalveolar lavage fluid; BW: body weight; eGFP: enhanced green
fluorescence protein; ELISA: enzyme linked immunosorbent assay; GFP: green
fluorescent protein; i.t.: intratracheally; IL: interleukin; KGF: keratinocyte growth
factor; LPS: lipopolysaccharide; LWW: lung wet weight; mMSC: mouse bone
marrow-derived mesenchymal stem cell; MSC: mesenchymal stem cell;
NS: normal saline; PBS: phosphate-buffered saline; SP-C: pro-surfactant protein C.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SXC carried out the molecular genetic studies, participated in the establishment
of animal model and drafted the manuscript. ARL conceived of the study, and
participated in its design and helped to draft the manuscript. SC participated in
the design of the study and performed the statistical analysis. HLH participated
in the design of the study and carried out the labelling and tracing of MSCs.
QHC carried out the immunofluorescent staining. JYX participated in the
biochemical analysis. CP carried out the Western immunoblot analysis. YY
participated in the design of the study and helped to draft the manuscript.
FMG carried out the haematoxylin and eosin staining, and participated in the
lung injury and fibrosis scoring. YZH carried out the Masson’s trichrome
staining, and participated in the lung injury and fibrosis scoring. LL participated
in the statistical analysis. HBQ participated in the design of the study and
helped to draft the manuscript. All authors have read and approved the final
version of the manuscript.Acknowledgments
This study was supported by the National Natural Science Foundation of
China (81070049; 81170057; 81201489; 81372093; 81300060; 81300043),
Natural Science Foundation of Jiangsu Province of China (BK2011600;
BK20131302), and Graduate Innovation Project in Jiangsu Province of China
(CXLX13_123; CXCL_151).
Author details
1Department of Critical Care Medicine, Zhong-da Hospital, School of
Medicine, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, People’s
Republic of China. 2Department of Critical Care Medicine, The Affiliated Hospital
of Qingdao University, 16 Jiangsu Road, Qingdao 266003, People’s Republic of
China. 3State Key Laboratory of Natural Medicines, School of Life Science and
Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009,
People’s Republic of China.
Received: 11 October 2014 Revised: 3 February 2015
Accepted: 20 March 2015
References
1. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress
syndrome. J Clin Invest. 2012;122:2731–40.
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al.
Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–93.
3. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J
Med. 2000;342:1334–49.
4. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al.
Mesenchymal stem cell engraftment in lung is enhanced in response to
bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U
S A. 2003;100:8407–11.
5. Yamada M, Kubo H, Kobayashi S, Ishizawa K, Numasaki M, Ueda S, et al.
Bone marrow-derived progenitor cells are important for lung repair after
lipopolysaccharide-induced lung injury. J Immunol. 2004;172:1266–72.
6. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC,
et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium.
Development. 2001;128:5181–8.
7. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary
delivery of bone marrow-derived mesenchymal stem cells improves survival
and attenuates endotoxin-induced acute lung injury in mice. J Immunol.
2007;179:1855–63.
8. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention
of LPS-induced acute lung injury in mice by mesenchymal stem cells
overexpressing angiopoietin 1. PLoS Med. 2007;4, e269.
9. Logan CY, Nusse R. The Wnt signaling pathway in development and
disease. Annu Rev Cell Dev Biol. 2004;20:781–810.
10. Etheridge SL, Spencer GJ, Heath DJ, Genever PG. Expression profiling and
functional analysis of wnt signaling mechanisms in mesenchymal stem cells.
Stem Cells. 2004;22:849–60.
11. Liu AR, Liu L, Chen S, Yang Y, Zhao HJ, Guo FM, et al. Activation of canonical wnt
pathway promotes differentiation of mouse bone marrow-derived MSCs into
type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes
their migration to injured lung tissue in vitro. J Cell Physiol. 2013;228:1270–83.
12. Cai SX, Liu AR, He HL, Chen QH, Yang Y, Guo FM, et al. Stable genetic
alterations of beta-catenin and ROR2 regulate the Wnt pathway, affect the
fate of MSCs. J Cell Physiol. 2014;229:791–800.
13. Fang WF, Cho JH, He Q, Lin MC, Wu CC, Voelkel NF, et al. Lipid A fraction of
LPS induces a discrete MAPK activation in acute lung injury. Am J Physiol
Lung Cell Mol Physiol. 2007;293:L336–44.
14. Mrozek JD, Smith KM, Bing DR, Meyers PA, Simonton SC, Connett JE, et al.
Exogenous surfactant and partial liquid ventilation: physiologic and
pathologic effects. Am J Respir Crit Care Med. 1997;156:1058–65.
15. Wang XY, Ju S, Li C, Peng XG, Chen AF, Mao H, et al. Non-invasive imaging
of endothelial progenitor cells in tumor neovascularization using a novel
dual-modality paramagnetic/near-infrared fluorescence probe. PLoS One.
2012;7, e50575.
16. Sun Z, Wang Y, Gong X, Su H, Han X. Secretion of rat tracheal epithelial
cells induces mesenchymal stem cells to differentiate into epithelial cells.
Cell Biol Int. 2012;36:169–75.
17. Dong L, He HL, Lu XM, Yang Y, Qiu HB. Modulation of FLT3 signaling
targets conventional dendritic cells to attenuate acute lung injury. APMIS.
2012;120:808–18.
Cai et al. Stem Cell Research & Therapy  (2015) 6:65 Page 11 of 1118. Chen Q, Yang Y, Huang Y, Pan C, Liu L, Qiu H. Angiotensin-(1-7) attenuates
lung fibrosis by way of Mas receptor in acute lung injury. J Surg Res.
2013;185:740–7.
19. Grove JE, Lutzko C, Priller J, Henegariu O, Theise ND, Kohn DB, et al.
Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary
epithelium. Am J Respir Cell Mol Biol. 2002;27:645–51.
20. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors,
and multiple transcription factors. J Biol Chem. 2006;281:22429–33.
21. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of
intravenous administration of bone marrow stromal cells after cerebral
ischemia in rats. Stroke. 2001;32:1005–11.
22. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J, et al.
Mesenchymal stem cells home to injured tissues when co-infused with
hematopoietic cells to treat a radiation-induced multi-organ failure
syndrome. J Gene Med. 2003;5:1028–38.
23. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal
stem cells distribute to a wide range of tissues following systemic infusion
into nonhuman primates. Blood. 2003;101:2999–3001.
24. Rochefort GY, Vaudin P, Bonnet N, Pages JC, Domenech J, Charbord P, et al.
Influence of hypoxia on the domiciliation of mesenchymal stem cells after
infusion into rats: possibilities of targeting pulmonary artery remodeling via
cells therapies? Respir Res. 2005;6:125.
25. Kollar K, Cook MM, Atkinson K, Brooke G. Molecular mechanisms involved in
mesenchymal stem cell migration to the site of acute myocardial infarction.
Int J Cell Biol. 2009;2009:904682.
26. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al.
Systemic delivery of bone marrow-derived mesenchymal stem cells to the
infarcted myocardium: feasibility, cell migration, and body distribution.
Circulation. 2003;108:863–8.
27. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, et al. Prevention of
endotoxin-induced systemic response by bone marrow-derived mesenchymal
stem cells in mice. Am J Physiol Lung Cell Mol Physiol. 2007;293:L131–41.
28. Neth P, Ciccarella M, Egea V, Hoelters J, Jochum M, Ries C. Wnt signaling
regulates the invasion capacity of human mesenchymal stem cells. Stem
Cells. 2006;24:1892–903.
29. Shang YC, Wang SH, Xiong F, Zhao CP, Peng FN, Feng SW, et al. Wnt3a
signaling promotes proliferation, myogenic differentiation, and migration of
rat bone marrow mesenchymal stem cells. Acta Pharmacol Sin.
2007;28:1761–74.
30. Matthay MA, Robriquet L, Fang X. Alveolar epithelium: role in lung fluid
balance and acute lung injury. Proc Am Thorac Soc. 2005;2:206–13.
31. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, et al. Has
mortality from acute respiratory distress syndrome decreased over time? A
systematic review. Am J Respir Crit Care Med. 2009;179:220–7.
32. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, et al. Bone marrow-
derived mesenchymal stem cells in repair of the injured lung. Am J Respir
Cell Mol Biol. 2005;33:145–52.
33. Ma N, Gai H, Mei J, Ding FB, Bao CR, Nguyen DM, et al. Bone marrow
mesenchymal stem cells can differentiate into type II alveolar epithelial cells
in vitro. Cell Biol Int. 2011;35:1261–6.
34. Liu KD, Matthay MA. Advances in critical care for the nephrologist: acute
lung injury/ARDS. Clin J Am Soc Nephrol. 2008;3:578–86.
35. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA.
Therapeutic effects of human mesenchymal stem cells in ex vivo human
lungs injured with live bacteria. Am J Respir Crit Care Med. 2013;187:751–60.
36. Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, et al.
Bone marrow derived mesenchymal stem cells inhibit inflammation and
preserve vascular endothelial integrity in the lungs after hemorrhagic shock.
PLoS One. 2011;6, e25171.
37. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction
proteins. Prog Biophys Mol Biol. 2003;81:1–44.
38. McCarthy KM, Skare IB, Stankewich MC, Furuse M, Tsukita S, Rogers RA, et al.
Occludin is a functional component of the tight junction. J Cell Sci.
1996;109:2287–98.
39. Zhang YL, Li QQ, Guo W, Huang Y, Yang J. Effects of chronic ethanol
ingestion on tight junction proteins and barrier function of alveolar
epithelium in the rat. Shock. 2007;28:245–52.
40. Akram KM, Samad S, Spiteri M, Forsyth NR. Mesenchymal stem cell therapy
and lung diseases. Adv Biochem Eng Biotechnol. 2013;130:105–29.
41. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the
coin. Tissue Antigens. 2007;69:1–9.42. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al.
Interaction of human mesenchymal stem cells with cells involved in
alloantigen-specific immune response favors the differentiation of CD4+
T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica.
2005;90:516–25.
43. Konigshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, Seeger W, et al.
Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS
One. 2008;3, e2142.
44. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, et al.
Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary
fibrosis. Am J Pathol. 2003;162:1495–502.
45. Tanjore H, Degryse AL, Crossno PF, Xu XC, McConaha ME, Jones BR, et al.
beta-catenin in the alveolar epithelium protects from lung fibrosis after
intratracheal bleomycin. Am J Respir Crit Care Med. 2013;187:630–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
